We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Low-Dose Rivaroxaban Fails to Significantly Reduce Left Ventricular Thrombosis in Anterior STEMI: Results of the APERITIF Trial

MedXY Editorial Team•Feb 27, 2026•Cardiology
anticoagulationCardiac Magnetic ResonanceRivaroxaban

Highlight

The APERITIF trial evaluated the efficacy of adding very low-dose rivaroxaban (2.5 mg twice daily) to dual antiplatelet therapy (DAPT) for the prevention of left ventricular (LV) thrombus in patients following anterior ST-segment elevation myocardial infarction (STEMI).

Primary results showed that LV thrombus occurred in 13.7% of the rivaroxaban group compared to 16.6% in the DAPT-only group, a difference that was not statistically significant (P = .34).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Innovative Anticoagulation: Targeting Factor XI with Amrecibart and Cenvacibart for Safer Thrombosis PreventionFactor XI-targeted antibodies, amrecibart and cenvacibart, offer promising anticoagulation by selectively inhibiting intrinsic coagulation pathways, potentially reducing thrombosis without increasing bleeding risk.Oct 17, 2026Bringing Cardiac MRI into Everyday Cardiology: Key Recommendations from the 2026 EHJ ConsensusA practical, clinician-focused summary of the 2026 European Heart Journal consensus on implementing cardiac magnetic resonance (CMR) across common cardiac diseases, highlighting indications, protocols, prognostic use, device safety, and worOct 4, 2026Efficacy and Safety of Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease with High Cardiovascular Risk: A Comprehensive ReviewLow-dose rivaroxaban failed to reduce cardiovascular events but increased major bleeding in advanced CKD patients at high cardiovascular risk, underscoring the need for cautious anticoagulant use.Sep 20, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Refining Right Ventricular Assessment in Pulmonary Hypertension: Impact of Postprocessing Techniques on Cardiac MRI Metrics
This study examines how cardiac MRI postprocessing methods, including trabeculation exclusion and pulmonary artery flow measurement sites, significantly influence right ventricular volume and function assessment in pulmonary hypertension pa
Sep 17, 2026
Ischaemic Stroke Risk in Atrial Flutter Versus Atrial Fibrillation: Insights from a Finnish Nationwide Registry StudyThis Finnish nationwide study demonstrates that patients with atrial flutter have a substantially lower risk of ischaemic stroke compared to those with atrial fibrillation, highlighting important differences in thromboembolic risk profilesSep 9, 2026
Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: Evidence and Insights from the NOTION-4 TrialThe NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding riskAug 31, 2026